FDA Rejects Replimune’s Melanoma Drug Again, Company Announces Layoffs
Updated
Updated · Reuters · Apr 10
FDA Rejects Replimune’s Melanoma Drug Again, Company Announces Layoffs
53 articles · Updated · Reuters · Apr 10
The US FDA has again rejected Replimune Group's RP1 drug for advanced melanoma, citing insufficient evidence from clinical studies.
Replimune disagreed with the decision, highlighting a 34% response rate in its IGNYTE trial and plans to scale back US operations and lay off staff.
The FDA's stance reflects stricter regulatory standards, leaving patients without this potential treatment and raising concerns about the approval process for innovative therapies.
Did the FDA truly move the goalposts, or did Replimune fail to meet consistent regulatory standards?
What does the RP1 rejection mean for advanced melanoma patients desperately seeking new treatment options?
How will this rejection impact investor confidence in the volatile biotech and oncolytic virus sector?
How will this case influence future clinical trial designs for combination immunotherapies?
Is the FDA striking the right balance between accelerating innovation and ensuring drug efficacy?
With a key CBER leader departing, will FDA's drug review standards become more predictable?